The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
about
Clinical perspectives on echinocandin resistance among Candida speciesEmerging issues with diagnosis and management of fungal infections in solid organ transplant recipientsEchinocandin resistance: an emerging clinical problem?Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Drug-resistant Candida glabrata infection in cancer patients.Abdominal candidiasis is a hidden reservoir of echinocandin resistance.Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology.Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Echinocandin Resistance in Candida.Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream InfectionStepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia.Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposureComparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin.Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.CD101: a novel long-acting echinocandin.Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata.Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.The evolving role of antifungal susceptibility testing.Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.The future of fungal susceptibility testing.Mechanisms of echinocandin antifungal drug resistance.Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Phenotypic and Molecular Evaluation of Echinocandin Susceptibility of Candida glabrata, Candida bracarensis, and Candida nivariensis Strains Isolated during 30 Years in Argentina.Management of candidemia in patients with Clostridium difficile infection.Echinocandin Resistance in Candida Species: a Review of Recent Developments.Caspofungin benefit on phagocytes from patients with renal dysfunction infected with multidrug-resistant Candida glabrata.Echinocandins in antifungal pharmacotherapy.Rapid Detection of FKS-Associated Echinocandin Resistance in Candida glabrataThe Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification.Candidiasis and the impact of flow cytometry on antifungal drug discovery.Relationship between the Antifungal Susceptibility Profile and the Production of Virulence-Related Hydrolytic Enzymes in Brazilian Clinical Strains of Candida glabrata.Echinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients.[Strategies for antifungal treatment failure in intensive care units].
P2860
Q28082538-E6C1E5B0-9CED-4797-A04A-B4C20B65C1C8Q28084643-A91BD7B2-3215-4EF9-A391-FBF934B29FE7Q28544739-40656826-92F9-4621-94DA-7970C372D3DBQ31032549-C78E8DB8-B6F8-4B52-8C5E-B9817F8EC458Q34058099-DB1E11ED-0CDC-4985-B6C6-02F6E7C12902Q34426755-8DE31432-D497-42E7-BF1C-1CA0AB78258DQ34597421-1317696B-E1A0-4D19-BA35-1771294F214AQ34653849-16A5C9BE-A71B-4C8E-9168-8E2C3CA37A82Q35880078-3454EDE0-B75B-419D-B1B5-9C3AA4F7E59AQ35960887-DEF3D823-4D5D-4874-9402-A44449828A95Q36158489-40B4BF8A-E379-468B-9D95-C0D939683E64Q36276186-C09C3886-A419-4C01-A373-21F50C25A925Q36290758-CE780342-069A-49B4-BBDC-1039E147AA8DQ36505494-4F156C1A-9BAD-4A0A-999F-1CE78EAF1D85Q37029566-97694F02-B109-4AC6-8751-79E688181019Q37036603-90A4E6B5-7253-4BE8-BCAE-618B2E98DB95Q37263358-D9194D7B-32CB-4E24-BA27-2BE5F0B9D23EQ37335848-EC0E24B7-D262-41BD-8CFD-E6F46D1705F0Q37394523-1D89CCAA-DB50-4A05-B794-867EA95043A0Q37643499-5CB9C8BF-74E9-45B7-901E-32CC2761B498Q38053482-BB99F93E-22AF-4BFD-BD79-AEFE88EA921CQ38095809-256E60F5-CAC0-456A-8818-CFD43147F866Q38236893-90DAAACD-D7D7-4320-9B6D-9A34A3A6FB98Q38254290-3B6631CF-F499-426B-B787-0E1347FA82E0Q38258833-E8979131-BEDD-40CC-87EF-68772084ACB3Q38550402-CCD34171-565B-4D62-BA82-1A02012BE07AQ38637592-FFAA1CD8-0188-4EB5-ADCC-78BB1D07411EQ38711698-E3AD18F8-3EDE-4D4D-B57E-6BBA35E9A894Q38810300-015DA199-D905-4CEF-8A3F-658B05E8C2E1Q38851595-DC212603-F627-4A02-A799-044F4CAA475DQ38988521-B1AB32B2-4064-4660-9DBB-26EF0EE8CA0FQ39388865-4342821B-8BA5-43CC-85BB-FAD4EBF48AABQ39458862-0167FBD1-2637-4E52-9F1F-7369016BAA40Q39464983-73651DC3-AE7B-4579-BFC8-49EA8A04D265Q40045635-2F885B1E-1864-473D-AA28-00A9F3689B58Q40045673-403B93FA-1484-495A-9DE4-D3EFB8DB387FQ40064579-D08C4D72-9A78-4D3D-9B4A-6265962FF2ECQ40090888-3C154DFD-2DCD-4EC1-B6C1-6F1CF255E21DQ40448192-CCA5B03F-68C8-49BF-AA00-B1CC6CB80C3CQ41010354-A126614F-91CF-446F-9634-0E0494FE223C
P2860
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The presence of an FKS mutatio ...... iasis due to Candida glabrata.
@ast
The presence of an FKS mutatio ...... iasis due to Candida glabrata.
@en
type
label
The presence of an FKS mutatio ...... iasis due to Candida glabrata.
@ast
The presence of an FKS mutatio ...... iasis due to Candida glabrata.
@en
prefLabel
The presence of an FKS mutatio ...... iasis due to Candida glabrata.
@ast
The presence of an FKS mutatio ...... iasis due to Candida glabrata.
@en
P2093
P2860
P921
P356
P1476
The presence of an FKS mutatio ...... iasis due to Candida glabrata.
@en
P2093
Andrea L Kwa
Cornelius J Clancy
Ellen G Press
M Hong Nguyen
Ryan K Shields
Shaoji Cheng
P2860
P304
P356
10.1128/AAC.00027-12
P407
P577
2012-07-02T00:00:00Z